CSL completes $275m Novartis vaccines acquisition

pharmafile | August 3, 2015 | News story | Manufacturing and Production, Sales and Marketing CSL, Novartis, acquisitions, asset swap, vaccines 

CSL Limited has finalised its transaction to acquire Novartis’s global influenza vaccine business for $275 million.

The move means Novartis has completed its exit of the vaccines market, following the divestment of its vaccines in an asset-swapping deal with GSK.

As part of the multi-billion dollar deal GSK acquired Novartis’ global human vaccines business (except the influenza vaccines unit) for $7.1 billion, and Novartis taking over GSK’s oncology business for up to $16 billion.

In a statement to the Australian Securities Exchange, CSL said the closing of the transaction will allow the company to integrate the influenza vaccines division with its subsidiary, bioCSL.

The combined business will create the $4 billion global industry’s second largest influenza vaccine business. bioCSL will have manufacturing plants in the US, UK, Germany and Australia, a commercial presence in some 20 countries, a differentiated product portfolio and strong pandemic and pre-pandemic franchises.

Since April 2014, the influenza vaccines unit results have been reported under discontinuing operations in the Novartis consolidated financial statements – and the figures show sales in this area have been dwindling since the announcement of the company’s market exit.

The company’s financial results for the second quarter of 2015 show its influenza vaccines sales were $39 million, compared to USD 29 million in the same period in 2014. Sales for the first half of 2015 were $56 million, compared to USD 81 million in 2014.

Novartis said the deal marks the end of a series of transactions aimed at focusing it on its three leading global-scale businesses: pharmaceuticals, generics and eye care.

Joel Levy

Related Content

Novartis shares new data about Fabhalta for IgAN treatment

Novartis has announced new results from a pre-specified interim analysis of its phase 3 APPLAUSE-IgAN …

Merck plans to conduct trials for HPV vaccines

Merck, known as MSD outside of the US and Canada, has announced that it is …

Measles: the UK’s next epidemic?

Recently, the UK has seen a rapid increase in the number of cases of measles, …

Latest content